Clidinium

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H26NO3
Molecular Weight	352.4467
Optical Activity	NONE
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(C3=CC=CC=C3)C4=CC=CC=C4

InChI

InChIKey=HOOSGZJRQIVJSZ-UHFFFAOYSA-N

InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1

HIDE SMILES / InChI

Molecular Formula	C22H25NO3
Molecular Weight	351.4388
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f99ebf66-f207-4a97-9666-4da1d72b061c&type
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00771

LIBRAX® combines in a single capsule formulation the antianxiety action of chlordiazepoxide hydrochloride and the anticholinergic/spasmolytic effects of clidinium bromide. Chlordiazepoxide hydrochloride is a versatile, therapeutic agent of proven value for the relief of anxiety and tension. It is indicated when anxiety, tension or apprehension are significant components of the clinical profile. It is among the safer of the effective psychopharmacologic compounds. Clidinium bromide is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. LIBRAX® is indicated to control emotional and somatic factors in gastrointestinal disorders. It may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor M3 159 Target ID: CHEMBL245 Sources: https://www.drugbank.ca/drugs/DB00771	Antagonist 2778		9.6 null [pKi]

Conditions

Condition	Modality	Highest Phase	Product
Intestinal spasm 2 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f99ebf66-f207-4a97-9666-4da1d72b061c&type	Curative	Approved 8429	LIBRAX Approved Use LIBRAX is indicated to control emotional and somatic factors in gastrointestinal disorders. Librax may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Launch Date 1966
Peptic ulcer 72 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f99ebf66-f207-4a97-9666-4da1d72b061c&type	Palliative	Approved 8429	LIBRAX Approved Use LIBRAX® is indicated to control emotional and somatic factors in gastrointestinal disorders. It may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Launch Date 1966
Irritable bowel syndrome 60 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f99ebf66-f207-4a97-9666-4da1d72b061c&type	Palliative	Approved 8429	LIBRAX Approved Use LIBRAX® is indicated to control emotional and somatic factors in gastrointestinal disorders. It may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Launch Date 1966
Acute enterocolitis 2 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f99ebf66-f207-4a97-9666-4da1d72b061c&type	Palliative	Approved 8429	LIBRAX Approved Use LIBRAX® is indicated to control emotional and somatic factors in gastrointestinal disorders. It may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Launch Date 1966

T_1/2

Value	Dose	Co-administered	Analyte	Population
20 h DRUG LABEL https://www.pdr.net/drug-summary/Librax-chlordiazepoxide-hydrochloride-clidinium-bromide-1626			CLIDINIUM unknown	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	OCT1 327

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
OCT1 327	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554776/	yes

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00I7CT
ABI Chem	AC1L1EGK
AbovChem LLC	HY-B1132
Angene	AGN-PC-0RA7TX
BOC Sciences	7020-55-5	https://www.bocsci.com/1-azoniabicyclo-2-2-2-octane-3-2-hydroxy-2-2-diphenylacetyl-oxy-1-methyl-cas-7020-55-5-item-149255.html
Bosche Scientific	C2272
Chem Scene	CS-4737
ChemTik	CTK7F4055
Chemieliva Pharmaceutical Co., Ltd	PBCM1390160
Compound Cloud	19004
Compound Cloud	2784
Hairui	HR100394
Hangzhou APIChem Technology	AC-13157
Hangzhou Yuhao Chemical Technology	RT18963
KeyOrganics	KS-1295
MedChem Express	HY-B1132
MolPort	MolPort-003-666-147
Molnova	M14193
MuseChem	I003275
Norris Pharm	NSZB-A001783
NovoSeek	2784
PI Chemicals	PI-27513
Selleck Chemicals	S5480
Sigma Aldrich	Q108
Sigma Aldrich	Q108\|SIGMA
THE BioTek	bt-428313	https://www.thebiotek.com/product/others/bt-428313
TargetMol	T0786
Tetrahedron	TS81995
TimTec	ST51014934
Toronto Research Chemicals	C576250
Toronto Research Chemicals	C587140
Vesino Industrial Co Ltd	VA10607
ZINC	ZINC000000601316	http://zinc15.docking.org/substances/ZINC000000601316
ZINC	ZINC000003830579	http://zinc15.docking.org/substances/ZINC000003830579
mcule	MCULE-6993268975	https://mcule.com/MCULE-6993268975/

PubMed

Title	Date	PubMed
Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line.	1998 Feb	9454790
Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor.	2006 Aug	16847442
Management of acute diarrhoea in primary care in Bahrain: self-reported practices of doctors.	2007 Jun	17985822
Palmar-plantar erythrodysesthesia caused by mercaptopurine and mesalamine.	2008 Aug	18711101
Spectrophotometric and chromatographic simultaneous estimation of amitriptyline hydrochloride and chlordiazepoxide in tablet dosage forms.	2009 Jul	20502562
Simultaneous spectrophotometric estimation of imipramine hydrochloride and chlordiazepoxide in tablets.	2009 Jul	20502561
Accidental acute clidinium toxicity.	2009 Jun	19465630
Simultaneous RP-HPLC Estimation of Trifluoperazine Hydrochloride and Chlordiazepoxide in Tablet Dosage Forms.	2009 Sep	20502574
A comparative analysis of the Libyan national essential medicines list and the WHO model list of essential medicines.	2010 Dec 2	21483564
Stability-indicating HPLC method for simultaneous determination of clidinium bromide and chlordiazepoxide in combined dosage forms.	2010 Mar	20223092
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003

Patents

Sample Use Guides

In Vivo Use Guide

Because of the varied individual responses to tranquilizers and anticholinergics, the optimum dosage of LIBRAX® varies with the diagnosis and response of the individual patient. The dosage, therefore, should be individualized for maximum beneficial effects. The usual maintenance dose is 1 or 2 capsules, 3 or 4 times a day administered before meals and at bedtime.

Route of Administration: Oral

In Vitro Use Guide

Binding of [3H]-NMeQNB (clidinium) to crude membranes of freshly isolated bovine aortic endothelial cells was atropine-displaceable and of high affinity (Kd = 0.48 nM) to a single class of sites (maximum binding capacity: 14 +/- 3 fmol/mg protein). Stereospecificity of the binding sites was demonstrated in experiments in which [3H]-NMeQNB binding was inhibited by dexetimide in the nanomolar range (Ki = 0.63 nM) and by levetimide, its stereoisomer in the micromolar range (Ki = 3.2 uM) (selectivity factor: approximately 5000). Binding of [3H]-NMeQNB to freshly harvested intact cells was also atropine-displaceable, stereospecific (selectivity factor: approximately 3500) and of high affinity (Kd = 0.35 nM). The maximum binding capacity (9 +/- 2 fmol/mg total cell protein) was comparable to that of membranes and corresponded to approximately 900 binding sites per endothelial cell.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:35:25 GMT 2023` Edited by `admin` on `Fri Dec 15 16:35:25 GMT 2023`
Record UNII	BO76JF850N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Clidinium

Common Name

English

1-Azoniabicyclo[2.2.2]octane, 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1-methyl-

Systematic Name

English

CLIDINIUM CATION

Common Name

English

CLIDINIUM [VANDF]

Common Name

English

Clidinium [WHO-DD]

Common Name

English

CLIDINIUM ION

Common Name

English

Classification Tree Code System Code

WHO-VATC

QA03CA02